Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Risk factors of severe COVID-19 in people with multiple sclerosis : A systematic review and meta-analysis
Masoud Etemadifar, Hosein Nouri, Mohammad Reza Maracy, et al.
Revue Neurologique (2021) Vol. 178, Iss. 1-2, pp. 121-128
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis
Masoud Etemadifar, Hosein Nouri, Maristella Pitzalis, et al.
Journal of Neurology Neurosurgery & Psychiatry (2022) Vol. 93, Iss. 9, pp. 986-994
Open Access | Times Cited: 33
Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies
Tyler Smith, Maya Madhavan, Daniel Gratch, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 60, pp. 103735-103735
Open Access | Times Cited: 27
Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort study
Masoud Etemadifar, Amir Parsa Abhari, Hosein Nouri, et al.
BMC Neurology (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 22
COVID‐19 vaccination hesitancy among people with chronic neurological disorders: A position paper
Martin Rakuša, Şerefnur Öztürk, Elena Moro, et al.
European Journal of Neurology (2022) Vol. 29, Iss. 8, pp. 2163-2172
Open Access | Times Cited: 22
Multiple sclerosis in the era of COVID-19: disease course, DMTs and SARS-CoV2 vaccinations
Maura Pugliatti, Thomas Berger, Hans‐Peter Hartung, et al.
Current Opinion in Neurology (2022) Vol. 35, Iss. 3, pp. 319-327
Closed Access | Times Cited: 18
Risk of MS relapse and deterioration after COVID-19: A systematic review and meta-analysis
Homa Seyedmirzaei, Dorsa Salabat, Sara KamaliZonouzi, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 83, pp. 105472-105472
Closed Access | Times Cited: 3
Who Is at Higher Risk of SARS-CoV-2 Reinfection? Results from a Northern Region of Italy
Maria Francesca Piazza, Daniela Amicizia, Francesca Marchini, et al.
Vaccines (2022) Vol. 10, Iss. 11, pp. 1885-1885
Open Access | Times Cited: 17
SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine
Masoud Etemadifar, Nahad Sedaghat, Hosein Nouri, et al.
Multiple Sclerosis and Related Disorders (2021) Vol. 57, pp. 103417-103417
Open Access | Times Cited: 19
The association between various viral infections and multiple sclerosis: An umbrella review on systematic review and meta‐analysis
Arash Bakhshi, Narges Eslami, Naeim Norouzi, et al.
Reviews in Medical Virology (2023) Vol. 34, Iss. 1
Closed Access | Times Cited: 7
Pre-existing neurological conditions and COVID-19 co-infection: Data from systematic reviews, meta-analyses, and scoping reviews
Abhilasha P. Boruah, Kiran T. Thakur, Sachin P. Gadani, et al.
Journal of the Neurological Sciences (2023) Vol. 455, pp. 120858-120858
Open Access | Times Cited: 6
Feasibility of Low-Load Resistance Training Using Blood Flow Restriction for People With Advanced Multiple Sclerosis: A Prospective Cohort Study
Mark M. Mañago, Evan T. Cohen, Enrique Álvarez, et al.
Physical Therapy (2023) Vol. 104, Iss. 1
Open Access | Times Cited: 5
Influence of Disease Modifying Treatment, Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Vaccination on Coronavirus Disease 2019 Risk and Outcome in Multiple Sclerosis and Neuromyelitis Optica
Jennifer Jessica Eisler, Giulio Disanto, Rosaria Sacco, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 17, pp. 5551-5551
Open Access | Times Cited: 4
Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in
Maura Pugliatti, Hans‐Peter Hartung, Celia Oreja‐Guevara, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 7
Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: A practical review and meta-analysis
Masoud Etemadifar, Hosein Nouri, Maristella Pitzalis, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 5
A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis
Marta Ponzano, Irene Schiavetti, Francesca Bovis, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 63, pp. 103909-103909
Open Access | Times Cited: 5
COVID-19 vaccination uptake in people with multiple sclerosis compared to the general population
Dijana Mayer, Barbara Barun, Karla Lazibat, et al.
Acta Neurologica Belgica (2023) Vol. 123, Iss. 6, pp. 2269-2275
Open Access | Times Cited: 2
Seroprevalence of SARS-CoV-2 in a Cohort of Patients with Multiple Sclerosis under Disease-Modifying Therapies
A. Sancho-Saldaña, Anna Gil-Sánchez, Bibiana Quirant, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 9, pp. 2509-2509
Open Access | Times Cited: 4
Effect of multiple sclerosis disease-modifying therapies on the real-world effectiveness of two doses of BBIBP-CorV (Sinopharm) vaccine
Masoud Etemadifar, Amir Parsa Abhari, Hosein Nouri, et al.
Journal of the Neurological Sciences (2022) Vol. 444, pp. 120518-120518
Open Access | Times Cited: 4
Effectiveness of tixagevimab/cilgavimab (Evusheld) in antiCD20‑treated patients with multiple sclerosis and neuromyelitis optica spectrum disorder
Dominika Šťastná, Marta Vachová, Pavel Dušek, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 85, pp. 105523-105523
Closed Access
Humoral immune response and safety of Sars-Cov-2 vaccine in people with multiple sclerosis
Seyedeh Sadigheh Hamzavi, Rosemina Bahrololoom, Sepideh Saeb, et al.
BMC Immunology (2024) Vol. 25, Iss. 1
Open Access
Clinical Course and Outcomes of COVID-19 in Patients with Multiple Sclerosis
Serap Zengin Karahan, Cavit Boz
Journal of Multiple Sclerosis Research (2024), pp. 16-22
Closed Access
Proximal Muscle Resistance Training to Improve Walking in People With Multiple Sclerosis: A Pilot Study
Mark M. Mañago, Jeri E. Forster, Eliza A. Biondi, et al.
Journal of Neurologic Physical Therapy (2024)
Closed Access
COVID-19 in Patients with Multiple Sclerosis – A narrative review
Bijay Kumar Shrestha, Eru Sujakhu, Smruti Karale, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 93, pp. 106221-106221
Closed Access
Effect of Disease-Modifying Therapies on Clinical Efficacy of COVID-19 Inactivated Vaccination among People with Multiple Sclerosis
Masoud Etemadifar, Amir Parsa Abhari, Hosein Nouri, et al.
SSRN Electronic Journal (2022)
Closed Access | Times Cited: 3
Ayurvedic management of neurological deficits post COVID-19 vaccination - A report of two cases
KM Pratap Shankar, Pratibha P Nair, Vara Saritha
Journal of Ayurveda and Integrative Medicine (2023) Vol. 14, Iss. 3, pp. 100737-100737
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top